Department of Cell and Developmental Biology, Knight Cancer Institute, Oregon Stem Cell Center, Portland, Oregon, USA.
Cancer Res. 2011 Feb 15;71(4):1497-505. doi: 10.1158/0008-5472.CAN-10-3223. Epub 2011 Feb 8.
The most deadly phase in cancer progression is attributed to the inappropriate acquisition of molecular machinery leading to metastatic transformation and spread of disease to distant organs. Although it is appreciated that metastasis involves epithelial-mesenchymal interplay, the underlying mechanism defining this process is poorly understood. Specifically, how cancer cells evade immune surveillance and gain the ability to navigate the circulatory system remains a focus. One possible mechanism underlying metastatic conversion is fusion between blood-derived immune cells and cancer cells. While this notion is a century old, in vivo evidence that cell fusion occurs within tumors and imparts genetic or physiologic changes remains controversial. We have previously demonstrated in vivo cell fusion between blood cells and intestinal epithelial cells in an injury setting. Here, we hypothesize that immune cells, such as macrophages, fuse with tumor cells imparting metastatic capabilities by transferring their cellular identity. We used parabiosis to introduce fluorescent-labeled bone marrow-derived cells to mice with intestinal tumors, finding that fusion between circulating blood-derived cells and tumor epithelium occurs during the natural course of tumorigenesis. Moreover, we identify the macrophage as a key cellular partner for this process. Interestingly, cell fusion hybrids retain a transcriptome identity characteristic of both parental derivatives, while also expressing a unique subset of transcripts. Our data supports the novel possibility that tumorigenic cell fusion may impart physical behavior attributed to migratory macrophages, including navigation of circulation and immune evasion. As such, cell fusion may represent a promising novel mechanism underlying the metastatic conversion of cancer cells.
癌症进展过程中最致命的阶段归因于分子机制的不适当获取,导致转移转化和疾病向远处器官扩散。尽管人们认识到转移涉及上皮-间充质相互作用,但定义这一过程的潜在机制仍知之甚少。具体来说,癌细胞如何逃避免疫监视并获得在循环系统中导航的能力仍然是一个焦点。转移性转化的一个可能机制是血液来源的免疫细胞和癌细胞之间的融合。虽然这一概念已有一个世纪的历史,但体内证据表明,肿瘤内确实发生细胞融合,并赋予遗传或生理变化,这一观点仍存在争议。我们之前已经在损伤环境中证明了体内血细胞和肠上皮细胞之间的细胞融合。在这里,我们假设免疫细胞,如巨噬细胞,通过转移其细胞身份与肿瘤细胞融合,赋予肿瘤转移能力。我们使用并体将荧光标记的骨髓来源细胞引入有肠道肿瘤的小鼠中,发现循环血液来源细胞与肿瘤上皮之间的融合发生在肿瘤发生的自然过程中。此外,我们确定巨噬细胞是这个过程的关键细胞伙伴。有趣的是,细胞融合杂种保留了与其亲本衍生物特征一致的转录组身份,同时还表达了一组独特的转录本。我们的数据支持了一个新的可能性,即肿瘤发生的细胞融合可能赋予与迁移巨噬细胞相关的物理行为,包括在循环中的导航和免疫逃避。因此,细胞融合可能代表了癌细胞转移转化的一个有前途的新机制。